Published in Circulation on November 01, 2004
Reversion of gene expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells. Cell Cycle (2011) 3.49
Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol (2008) 2.83
Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol (2012) 2.47
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med (2010) 2.21
Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail (2014) 2.14
Matricellular proteins in cardiac adaptation and disease. Physiol Rev (2012) 2.01
Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail (2010) 1.94
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol (2008) 1.94
Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail (2015) 1.46
Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail (2011) 1.45
Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol (2011) 1.44
Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep (2010) 1.37
Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron (2008) 1.26
Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol (2007) 1.26
Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. J Card Fail (2015) 1.12
Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One (2011) 1.10
Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol (2013) 1.06
Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. J Exp Med (2007) 1.06
Novel biomarkers in chronic heart failure. Nat Rev Cardiol (2012) 1.06
Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol (2010) 1.06
Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc (2012) 1.04
Heart-kidney crosstalk and role of humoral signaling in critical illness. Crit Care (2014) 1.02
Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol (2012) 1.01
CD36 and Na/K-ATPase-α1 form a proinflammatory signaling loop in kidney. Hypertension (2012) 0.99
Galectin 3 and incident atrial fibrillation in the community. Am Heart J (2014) 0.91
Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. J Mol Cell Cardiol (2015) 0.91
Cardiac oxidative stress in a mouse model of neutral lipid storage disease. Biochim Biophys Acta (2013) 0.90
Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology (2013) 0.90
Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis. Am J Pathol (2016) 0.89
Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc (2014) 0.88
Statins in heart failure: do we need another trial? Vasc Health Risk Manag (2013) 0.88
New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy. J Cardiovasc Transl Res (2013) 0.87
Biomarkers in acute heart failure--state of the art. Nat Rev Cardiol (2012) 0.87
Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc (2014) 0.87
Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD? Inflamm Res (2009) 0.85
Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities. Am J Respir Crit Care Med (2016) 0.85
Cirrhotic cardiomyopathy. World J Gastroenterol (2015) 0.84
Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. Am Heart J (2014) 0.83
Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. Heart Vessels (2015) 0.82
Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers (2012) 0.82
Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta (2014) 0.81
Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm (2014) 0.81
Galectin-3 in heart failure: more answers or more questions? J Am Heart Assoc (2012) 0.81
Resting and injury-induced inflamed periosteum contain multiple macrophage subsets that are located at sites of bone growth and regeneration. Immunol Cell Biol (2016) 0.81
Acute heart failure: patient characteristics and pathophysiology. Curr Heart Fail Rep (2013) 0.80
Novel renal biomarkers to assess cardiorenal syndrome. Curr Heart Fail Rep (2014) 0.80
Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail (2013) 0.80
Nuclear presence of adhesion-/growth-regulatory galectins in normal/malignant cells of squamous epithelial origin. Histochem Cell Biol (2005) 0.80
Macrophages During the Fibrotic Process: M2 as Friend and Foe. Front Immunol (2015) 0.79
Differential patterns of replacement and reactive fibrosis in pressure and volume overload are related to the propensity for ischaemia and involve resistin. J Physiol (2013) 0.79
Prognostic value of galectin-3 in patients with heart failure. Dis Markers (2015) 0.79
Glycoproteins identified from heart failure and treatment models. Proteomics (2014) 0.79
A novel phenylpyridazinone, T-3999, reduces the progression of autoimmune myocarditis to dilated cardiomyopathy. Heart Vessels (2010) 0.79
Galectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation. J Am Heart Assoc (2016) 0.78
Prognostic biomarkers in acute coronary syndrome. Ann Transl Med (2016) 0.78
The Role of Galectin-3 in the Kidneys. Int J Mol Sci (2016) 0.78
Vitamin D receptor genetics on extracellular matrix biomarkers and hemodynamics in systolic heart failure. J Cardiovasc Pharmacol Ther (2014) 0.78
Current Perspectives on rosuvastatin. Integr Blood Press Control (2013) 0.78
Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure. Int J Med Sci (2014) 0.78
DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy. PLoS One (2012) 0.78
Heart failure and galectin 3. Ann Transl Med (2014) 0.78
Plasma galectin 3 and heart failure risk in the Physicians' Health Study. Eur J Heart Fail (2013) 0.78
Emerging biomarkers in heart failure and cardiac cachexia. Int J Mol Sci (2014) 0.78
Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation. BMC Cardiovasc Disord (2016) 0.78
Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure. Biomed Res Int (2014) 0.78
Renal dysfunction in acute congestive heart failure: a common problem for cardiologists and nephrologists. Heart Fail Rev (2014) 0.78
Serial galectin-3 and future cardiovascular disease in the general population. Heart (2016) 0.77
Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. BMC Cardiovasc Disord (2016) 0.77
The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists. PLoS One (2015) 0.77
Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies. Clin Med Insights Cardiol (2015) 0.77
Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol (2016) 0.77
Effect of Age, Estrogen Status, and Late-Life GPER Activation on Cardiac Structure and Function in the Fischer344×Brown Norway Female Rat. J Gerontol A Biol Sci Med Sci (2016) 0.77
Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci Rep (2015) 0.77
Acute and chronic rejection: compartmentalization and kinetics of counterbalancing signals in cardiac transplants. Am J Transplant (2015) 0.76
Does cirrhotic cardiomyopathy exist? 50 years of uncertainty. Clin Res Cardiol (2013) 0.76
Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. AIDS (2016) 0.76
Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients. Int J Cardiovasc Imaging (2016) 0.76
Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans. PLoS One (2014) 0.76
Assessment of Galectin-3 Polymorphism in Subjects with Chronic Chagas Disease. Arq Bras Cardiol (2015) 0.76
Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling. Heart Lung Circ (2016) 0.75
Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy. J Interv Card Electrophysiol (2015) 0.75
ST2 and Galectin-3: Ready for Prime Time? EJIFCC (2016) 0.75
Expression of galectin-3 as a testis inflammatory marker in vasectomised mice. Cell J (2013) 0.75
Galectin-3 inhibition ameliorates hypoxia-induced pulmonary artery hypertension. Mol Med Rep (2016) 0.75
Galectin-3 Serum Levels Are Independently Associated With Microalbuminuria in Chronic Heart Failure Outpatients. Res Cardiovasc Med (2015) 0.75
Role for Galectin-3 in Calcific Aortic Valve Stenosis. J Am Heart Assoc (2016) 0.75
Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation. Sci Rep (2017) 0.75
Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure. PLoS One (2015) 0.75
Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke. Sci Rep (2017) 0.75
Doxazosin Stimulates Galectin-3 Expression and Collagen Synthesis in HL-1 Cardiomyocytes Independent of Protein Kinase C Pathway. Front Pharmacol (2016) 0.75
Role of point of care - ST2, Galectin-3 and adrenomedullin in the evaluation and treatment of emergency patients. Int J Crit Illn Inj Sci (2014) 0.75
Cardiac dysfunction in Pkd1-deficient mice with phenotype rescue by galectin-3 knockout. Kidney Int (2016) 0.75
Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol (2016) 0.75
Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study. BMC Cardiovasc Disord (2013) 0.75
Labeling galectin-3 for the assessment of myocardial infarction in rats. EJNMMI Res (2014) 0.75
Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging. Dis Markers (2016) 0.75
Identification of the Mtus1 Splice Variant as a Novel Inhibitory Factor Against Cardiac Hypertrophy. J Am Heart Assoc (2016) 0.75
Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve. BMC Cardiovasc Disord (2017) 0.75
Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Curr Heart Fail Rep (2017) 0.75
The quest for biomarker discovery in pulmonary arterial hypertension: the right takes lessons from the left. Heart (2016) 0.75
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry (2007) 4.44
Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res (2012) 4.06
miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res (2008) 3.96
MiR423-5p as a circulating biomarker for heart failure. Circ Res (2010) 3.83
Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet (2010) 3.75
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2013) 3.50
Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation (2008) 2.95
Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol (2005) 2.93
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J (2005) 2.93
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81
Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol (2012) 2.80
Neurologic Injury in Adults Supported With Veno-Venous Extracorporeal Membrane Oxygenation for Respiratory Failure: Findings From the Extracorporeal Life Support Organization Database. Crit Care Med (2017) 2.67
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol (2010) 2.50
Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest (2005) 2.50
Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry (2006) 2.41
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol (2012) 2.28
Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J (2005) 2.28
Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem (2003) 2.27
Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol (2011) 2.19
Who is at risk of post-MI depressive symptoms? J Psychosom Res (2005) 2.18
Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol (2009) 2.16
Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med (2006) 2.16
Reversible isolated left ventricular non-compaction? Int J Cardiol (2008) 2.15
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol (2004) 2.10
Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA (2008) 2.09
Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol (2013) 2.08
Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol (2013) 1.99
Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation (2003) 1.96
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol (2008) 1.94
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest (2011) 1.94
Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A (2007) 1.92
Relation of levels of serum lipoproteins to depression after acute myocardial infarction. Am J Cardiol (2002) 1.92
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res (2010) 1.90
Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol (2009) 1.87
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84
MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell (2011) 1.84
Chemical biology of the sugar code. Chembiochem (2004) 1.78
Depression following myocardial infarction: first-ever versus ongoing and recurrent episodes. Gen Hosp Psychiatry (2005) 1.76
Post-mortem histologic evaluation of microwave lesions after epicardial pulmonary vein isolation for atrial fibrillation. Ann Thorac Surg (2005) 1.73
Acute results of transvenous cryoablation of supraventricular tachycardia (atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia). J Cardiovasc Electrophysiol (2002) 1.72
Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol (2005) 1.71
Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J (2005) 1.71
Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol (2005) 1.69
Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace (2008) 1.68
Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace (2012) 1.67
Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet (2008) 1.67
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J (2008) 1.64
Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol (2006) 1.63
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J (2003) 1.63
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace (2011) 1.61
Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J (2011) 1.60
The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace (2010) 1.59
Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace (2011) 1.57
Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate. J Cardiovasc Electrophysiol (2004) 1.57
Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding. J Mol Biol (2004) 1.57
Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J (2008) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation (2005) 1.55
Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J (2004) 1.54
Calculation of effective VV interval facilitates optimization of AV delay and VV interval in cardiac resynchronization therapy. Heart Rhythm (2006) 1.54
Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension (2006) 1.53
The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest (2005) 1.51
Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol (2008) 1.51
The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol (2011) 1.51
Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J (2008) 1.51
Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res (2004) 1.51
Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens (2002) 1.50
Mouse strain determines the outcome of wound healing after myocardial infarction. Cardiovasc Res (2009) 1.49
Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol (2012) 1.48
From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem Sci (2011) 1.46